Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 5 days | $ 1,240.00 | |
25 mg | 5 days | $ 2,130.00 |
Description | BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively. |
Targets&IC50 | FLT3:19 nM , AURKA:22 nM |
In vitro | BPR1K871 demonstrates strong anti-proliferative effects on MOLM-13 and MV4-11 AML cells, achieving an EC50 of approximately 5 nM [1]. |
In vivo | BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) as well as solid tumors [1]. |
Synonyms | DBPR114 |
Molecular Weight | 526.05 |
Formula | C25H28ClN7O2S |
CAS No. | 2443767-35-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (237.62 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BPR1K871 2443767-35-7 Angiogenesis Tyrosine Kinase/Adaptors FLT DBPR-114 DBPR 114 BPR1K 871 BPR1K-871 DBPR114 BPR-1K871 inhibitor inhibit